Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P, McGuire JR, Iglesias J.

Clin Breast Cancer. 2012 Oct;12(5):313-21. doi: 10.1016/j.clbc.2012.05.001. Epub 2012 Jun 23.

PMID:
22728026
[PubMed - indexed for MEDLINE]
2.

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P.

J Clin Oncol. 2009 Aug 1;27(22):3611-9. doi: 10.1200/JCO.2008.18.5397. Epub 2009 May 26. Erratum in: J Clin Oncol. 2011 Jul 1;29(19):2739.

PMID:
19470941
[PubMed - indexed for MEDLINE]
3.

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.

Dranitsaris G, Coleman R, Gradishar W.

Breast Cancer Res Treat. 2010 Feb;119(3):717-24. doi: 10.1007/s10549-009-0424-z. Epub 2009 Jun 3.

PMID:
19495958
[PubMed - indexed for MEDLINE]
4.

Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.

Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis CA.

Clin Breast Cancer. 2013 Aug;13(4):239-246.e1. doi: 10.1016/j.clbc.2013.02.008.

PMID:
23829890
[PubMed - indexed for MEDLINE]
5.

Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.

Aapro M, Tjulandin S, Bhar P, Gradishar W.

Breast. 2011 Oct;20(5):468-74. doi: 10.1016/j.breast.2011.07.005. Epub 2011 Aug 16.

PMID:
21843943
[PubMed - indexed for MEDLINE]
6.

A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.

Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, Yablonsky PK, Bhar P, Iglesias J.

J Thorac Oncol. 2010 Jun;5(6):852-61.

PMID:
20521351
[PubMed - indexed for MEDLINE]
7.

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF.

J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30.

PMID:
22547591
[PubMed - indexed for MEDLINE]
8.

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group.

Ann Oncol. 2009 Mar;20(3):449-53. doi: 10.1093/annonc/mdn661. Epub 2008 Dec 15.

PMID:
19087987
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group.

J Clin Oncol. 2003 Mar 15;21(6):968-75. Erratum in: J Clin Oncol. 2003 May 15;21(10):2048.

PMID:
12637459
[PubMed - indexed for MEDLINE]
10.

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.

Dranitsaris G, Cottrell W, Spirovski B, Hopkins S.

J Oncol Pharm Pract. 2009 Jun;15(2):67-78. doi: 10.1177/1078155208098584. Epub 2008 Nov 26.

PMID:
19036903
[PubMed - indexed for MEDLINE]
11.

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X.

Breast Cancer Res Treat. 2013 Jun;139(2):411-9. doi: 10.1007/s10549-013-2552-8. Epub 2013 May 7.

PMID:
23649189
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group.

J Clin Oncol. 2004 Jul 1;22(13):2587-93.

PMID:
15226326
[PubMed - indexed for MEDLINE]
13.

An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

Benedict A, Cameron DA, Corson H, Jones SE.

Pharmacoeconomics. 2009;27(10):847-59. doi: 10.2165/10899510-000000000-00000.

PMID:
19803539
[PubMed - indexed for MEDLINE]
14.

Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.

O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J.

Breast Cancer Res Treat. 2013 Apr;138(3):829-37. doi: 10.1007/s10549-013-2447-8. Epub 2013 Apr 6.

PMID:
23563958
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.

Moon YW, Sohn JH, Choi HJ, Chang H, Park BW, Kim SI, Park S, Koo JS, Kim YT, Roh JK, Chung HC, Kim JH.

Cancer Chemother Pharmacol. 2010 Aug;66(3):425-31. doi: 10.1007/s00280-009-1176-5. Epub 2009 Dec 15.

PMID:
20012956
[PubMed - indexed for MEDLINE]
16.

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.

Yardley D, Burris H 3rd, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D, Hainsworth J.

Breast Cancer Res Treat. 2010 Sep;123(2):471-5. doi: 10.1007/s10549-010-1047-0. Epub 2010 Jul 24.

PMID:
20658263
[PubMed - indexed for MEDLINE]
17.

A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.

Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M.

Clin Breast Cancer. 2011 Apr;11(2):121-8. doi: 10.1016/j.clbc.2011.03.007. Epub 2011 Apr 11.

PMID:
21569998
[PubMed - indexed for MEDLINE]
18.

Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.

Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G.

Oncology. 2009;77(3-4):212-6. doi: 10.1159/000236021. Epub 2009 Sep 4.

PMID:
19729979
[PubMed - indexed for MEDLINE]
19.

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.

Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F.

BMC Cancer. 2013 Mar 28;13:164. doi: 10.1186/1471-2407-13-164.

PMID:
23537313
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.

Stemmler HJ, Harbeck N, Gröll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, Artmann A, Sommer H, Meerpohl HG, Kiechle M, Heinemann V.

Oncology. 2010;79(3-4):204-10. doi: 10.1159/000320625. Epub 2011 Mar 1.

PMID:
21358208
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk